Coronary heart disease (CHD) is the leading cause of death and disability in Europe. For
patients presenting with an acute ST-segment elevation myocardial infarction (STEMI) …

Ischemic diseases in an aging population pose a heavy social encumbrance. Moreover,
current therapeutic approaches, which aimed to prevent or minimize ischemia-induced …

Background—The effect of β-blockers on infarct size when used in conjunction with primary
percutaneous coronary intervention is unknown. We hypothesize that metoprolol reduces …

Abstract The β1-adrenergic-receptor (ADRB1) antagonist metoprolol reduces infarct size in
acute myocardial infarction (AMI) patients. The prevailing view has been that metoprolol acts …

Background: The impact of intravenous (IV) beta-blockers before primary percutaneous
coronary intervention (PPCI) on infarct size and clinical outcomes is not well established …

Objectives: The goal of this trial was to study the long-term effects of intravenous (IV)
metoprolol administration before reperfusion on left ventricular (LV) function and clinical …

Beta-blockers are the cornerstone of treatment for various cardiovascular conditions.
Although their effects have classically been considered to be driven by their antagonistic …

Background: Pre-reperfusion administration of intravenous (IV) metoprolol reduces infarct
size in ST-segment elevation myocardial infarction (STEMI). Objectives: This study sought to …

Selective stimulation of β 3 adrenergic-receptor (β3AR) has been shown to reduce infarct
size in a mouse model of myocardial ischemia/reperfusion. However, its functional long-term …

Background Autologous adipose tissue–derived mesenchymal stem cells (ATMSC s)
therapy is a promising strategy to improve post–myocardial infarction outcomes. In a porcine …